STOCKHOLM, June 14, 2017 /PRNewswire/ -- Fluicell AB is extremely pleased to announce the approval from the USPTO, of Patent No. 9,658,240, entitled 'Microfluidic device with holding interface, and methods of use'. This is the second patent approved for their transformational BioPen product line, which facilitates complex cell biology experiments at single-cell level, at affordable prices. This approval gives further recognition to the Fluicell team as innovation leaders, and solution providers for cell biology research and discovery tools for the 21st century.
Fluicell is an exciting Swedish high-tech company that brings inspiration and innovation to life science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within; cell biology, bioprinting, and secondary drug screening and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces costs, resource use, and animals. Fluicell's main target sectors include universities, the pharmaceutical industry, and national health laboratories.
This information was brought to you by Cision http://news.cision.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fluicell-receives-green-light-with-a-new-biopen-patent-in-the-usa-300473806.html